About Pancreatic Cancer
Pancreatic cancer is the second most common cancer treated by gastrointestinal surgeons in the United States; it is the fourth most common cause of cancer death in men and women in the U.S. According to the American Cancer Society, 43,920 new cases of pancreatic cancer and 37,390 deaths were expected in 2012.
Part of the reason for the high death rate is that pancreatic cancer is difficult to detect in the early stages. But at MUSC, we are changing what’s possible for advanced pancreatic cancer by using a multidisciplinary, patient-focused team of medical professionals who have expertise in successfully treating these tumors. We've combined the expertise of our renowned Digestive Disease Center with the leading-edge care and research of Hollings Cancer Center - South Carolina's only NCI-designated cancer center.
Our medical and radiation oncologists shrink tumors that would otherwise be inoperable so they may be removed surgically, increasing the long-term survival rate for those patients by three times. Likewise, our surgeons have the expertise to resect (cut out) challenging tumors that will require advanced reconstruction, for example, of arteries or other vessels that carry important bodily fluids. Because of all these factors, the MUSC Pancreas Surgery Program of Excellence is a destination center for cancer treatment.